share_log

公告精选 | 紫金矿业Q1归母净利同比增长15%;泡泡玛特首季海外收入增超240%

Featured announcements | Zijin Mining's Q1 net profit increased 15% year over year; Bubble Mart's overseas revenue increased by more than 240% in the first quarter

cls.cn ·  Apr 23 08:07

① China Mobile's net profit for the first quarter was nearly 30 billion yuan. How big is the profit scale? ② Bubble Mart's overseas revenue increased by more than 240% in the first quarter. How is the domestic market performing?

The important announcements for Hong Kong stocks yesterday are as follows:

Quarterly Report Summary

$CHINA MOBILE (00941.HK)$: Operating revenue for the first quarter was RMB 263.7 billion, up 5.2% year on year; of these, revenue from communications services was RMB 219.3 billion, up 4.5% year on year. Profit attributable to shareholders was 29.6 billion yuan, an increase of 5.5% over the previous year.

$ZIJIN MINING (02899.HK)$Net profit for the first quarter was 6.261 billion yuan, an increase of 15% over the previous year.

Zijin Mining announced that from January to March 2024, the company's mineral gold production increased 5% year on year, mineral copper production increased 5% year on year, and mineral zinc production decreased 9% year on year; achieved operating income of 74.777 billion yuan, down 0.22% year on year, realized net profit to mother of 6.261 billion yuan, an increase of 15% year on year, and gross margin of mining enterprises was 54.50%, up 0.97 percentage points year on year.

$WH GROUP (00288.HK)$: Revenue for the first quarter was US$6.181 billion, down 8.33% year on year; net profit before adjustment was US$301 million, up 73% year on year.

$BANK OF TIANJIN (01578.HK)$: Revenue for the first quarter was 4.117 billion yuan, up 6.03% year on year; total profit was 1,149 billion yuan, up 1.86% year on year.

$CH OVS G OCEANS (00081.HK)$: Revenue for the first quarter was about 7.499 billion yuan, down 17.5% year on year; net operating profit was 776 million yuan, down 37.1% year on year.

Company news

$POP MART (09992.HK)$: Overall revenue for the first quarter increased by 40%-45% year on year; of these, revenue from mainland China increased by 20%-25% year on year, and revenue from Hong Kong, Macao, Taiwan and overseas increased 245%-250% year on year.

By channel, retail stores grew 20%-25% year over year; robot stores increased 15% to 20% year over year; bubble mart box drawers increased 0%-5% year over year; e-commerce platforms and other online platforms increased 20% to 25% year over year; and wholesale and other channels increased 50%-55% year over year.

$LI NING (02331.HK)$: In the first quarter, retail sales at Li Ning's sales outlets increased by low number of units year over year.

Among them, offline channels (including retail and wholesale) achieved a decline in the number of units obtained. Among them, the number of units obtained by retail (direct management) channels increased, the number of units obtained by the wholesale (authorized dealer) channel decreased; and the e-commerce virtual store business achieved a low growth of 20%-30%.

$CHABAIDAO (02555.HK)$The issue price for the Hong Kong IPO was set at HK$17.50 per share, with a net raise of HK$2,463 million.

$CHINA RAIL CONS (01186.HK)$: The amount of new contracts signed in the first quarter was 55,689.5 billion yuan, an increase of 2.05% over the previous year.

$DATANG POWER (00991.HK)$: The cumulative feed-in capacity in the first quarter was about 59.861.9 billion kilowatt-hours, an increase of about 12.82% over the previous year.

$CHINA RE (01508.HK)$: The total original premium income of Dadi Financial Insurance was about 15.038 billion yuan, an increase of 0.15% over the previous year.

$YIDA CHINA (03639.HK)$: The subsidiary plans to sell all shares in Dalian Science and Technology City Xinrui Development and Dalian Science and Technology City Terry Development for 113 million yuan.

$CANSINOBIO (06185.HK)$: The freeze-dried Haemophilus influenzae type b (Hib) conjugate vaccine (Hib vaccine) developed by the company has been approved by the State Drug Administration of the People's Republic of China, and relevant clinical trials can be carried out.

$SH PHARMA (02607.HK)$: The application for clinical trials of the WST03 formulation was accepted.

$BAIYUNSHAN PH (00874.HK)$: Cefixime tablets passed the generic drug consistency evaluation.

Stock and repurchase trends

$HSBC HOLDINGS (00005.HK)$: Approximately HK$78.036,700 were spent to repurchase 1,266,800 shares at a repurchase price of HK$61.25-62.

$HANG SENG BANK (00011.HK)$: Spend HK$583.405 million to repurchase 600,000 shares at a repurchase price of HK$96.5-98.7.

$XIAOMI-W (01810.HK)$: On April 22, 3 million shares were purchased at HK$47.4 million.

$CSPC PHARMA (01093.HK)$: On April 22, 4,628 million shares were purchased at HK$27.592,700.

$WUXI BIO (02269.HK)$: On April 22, 1.55 million shares were purchased at HK$1.91 million.

$TUHU-W (09690.HK)$: On April 22, 980,000 shares were purchased at HK$17.72 million.

$CHINASOFT INT'L (00354.HK)$: On April 22, 3 million shares were purchased at HK$13.2893 million.

$XUANWU CLOUD (02392.HK)$: It is proposed to use up to HK$100 million to repurchase shares.

$ZHAOJIN MINING (01818.HK)$: Completed the placement of 132 million shares for the placement price of HK$13.20.

edit/ruby

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment